Individual generic drug information

letrozole

Reference monograph

Part of registered formulation

LETROZOLE

Reference record: Letrozole
Source: BNF 80 (2020–2021)
Printed source pages: 1029
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Letrozole only.

Indications And Dose

First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer | Adjuvant treatment of oestrogen-receptor-positive invasive early breast cancer in postmenopausal women | Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom other anti- oestrogen therapy has failed | Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years | Neo-adjuvant treatment in postmenopausal women with localised hormone-receptor-positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated ▶BY MOUTH ▶Adult: 2.5 mg daily

Source page 1029

Contra Indications

Not indicated for premenopausal women

Source page 1029

Cautions

Susceptibility to osteoporosis

Source page 1029

Safety

Extracted information for Letrozole only.

Side Effects

▶Common or very common Alopecia. appetite abnormal. arthralgia. asthenia. bone fracture. bone pain. constipation. depression. diarrhoea. dizziness. gastrointestinal discomfort. headache. hot ﬂush. hypercholesterolaemia. hyperhidrosis. hypertension. malaise. myalgia. nausea. oedema. osteoporosis. skin reactions. vaginal haemorrhage. vomiting. weight changes ▶Uncommon Anxiety. arthritis. breast pain. cancer pain. carpal tunnel syndrome. cataract. cerebrovascular insufﬁciency. cough. drowsiness. dry mouth. dysaesthesia. dyspnoea. embolism and thrombosis. eye irritation. fever. insomnia. irritability. ischaemic heart disease. leucopenia. memory loss. mucosal dryness. myocardial infarction. palpitations. stomatitis. tachycardia. taste altered. thirst. urinary frequency increased. urinary tract infection. vision blurred. vulvovaginal disorders ▶Frequency not known Angioedema. hepatitis. toxic epidermal necrolysis. trigger ﬁnger

Source page 1029

Conception And Contraception

Manufacturer advises effective contraception required until postmenopausal status fully established (return of ovarian function reported in postmenopausal women).

Source page 1029

Pregnancy

Avoid (isolated cases of birth defects reported).

Source page 1029

Breast Feeding

Manufacturer advises avoid.

Source page 1029

Hepatic Impairment

Manufacturer advises caution in severe impairment (increased exposure and half-life).

Source page 1029

Renal Impairment

Manufacturer advises caution if creatinine clearance less than 10 mL/minute.

Source page 1029

Monitoring Requirements

▶Osteoporosis Assess bone mineral density before treatment and at regular intervals.

Source page 1029

Dose and formulations

Extracted information for Letrozole only.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Letrozole (Non-proprietary) Letrozole 2.5 mg Letrozole 2.5mg tablets | 14 tablet P £49.90 DT = £1.16 | 28 tablet P £2.04–£84.86 ▶Femara (Novartis Pharmaceuticals UK Ltd) Letrozole 2.5 mg Femara 2.5mg tablets | 30 tablet P £90.92 Immunotherapy responsive malignancy ANTINEOPLASTIC DRUGS › ANTINEOPLASTICS, OTHER

Source page 1029

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2.5 mg daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1029

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

letrozole

Reference monograph

Part of registered formulation

LETROZOLE

Reference record: Letrozole
Source: BNF 80 (2020–2021)
Printed source pages: 1029
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Letrozole only.

Indications And Dose

Source page 1029

Contra Indications

Not indicated for premenopausal women

Source page 1029

Cautions

Susceptibility to osteoporosis

Source page 1029

Safety

Extracted information for Letrozole only.

Side Effects

Source page 1029

Conception And Contraception

Manufacturer advises effective contraception required until postmenopausal status fully established (return of ovarian function reported in postmenopausal women).

Source page 1029

Pregnancy

Avoid (isolated cases of birth defects reported).

Source page 1029

Breast Feeding

Manufacturer advises avoid.

Source page 1029

Hepatic Impairment

Manufacturer advises caution in severe impairment (increased exposure and half-life).

Source page 1029

Renal Impairment

Manufacturer advises caution if creatinine clearance less than 10 mL/minute.

Source page 1029

Monitoring Requirements

▶Osteoporosis Assess bone mineral density before treatment and at regular intervals.

Source page 1029

Dose and formulations

Extracted information for Letrozole only.

Medicinal Forms

Source page 1029

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

2.5 mg daily

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1029

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.